Breath analysis for acute myeloid leukemia treatment guidance
Part of Blood & lymphatic, Cancer clinical trials.
This study uses a breath test to quickly identify the specific type of acute myeloid leukemia (AML) and predict how well treatment might work. It aims to help doctors choose the best therapy for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) and are currently receiving treatment.
- OR you are undergoing an autologous stem cell transplant (using your own cells) for lymphoma or myeloma that is in remission.
- You are able to perform a breath test (blow into a mouthpiece).
- There are no physical barriers that would prevent you from using the mouthpiece.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This study is looking at a substance called leptin in the blood of people with newly diagnosed acute myeloid leukemia (AML). The goal is to see if leptin levels can help doctors predict how well chemotherapy will work, which could guide better treatment choices.
This trial studies whether the levels of certain proteins and blood clotting factors in your blood can help doctors understand acute myeloid leukemia better. It may lead to better ways to monitor the disease and its effects on your body.
This trial tests if a simple breath analysis can detect invasive fungal infections early in people with acute leukemia who are undergoing chemotherapy and have a low white blood cell count. Early detection could help start treatment sooner.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This study tests a new device that analyzes your breath to help monitor diseases. It may help doctors track conditions early, before treatment begins.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.